MON-154 Breast areolar diameter in healthy menstruating women—a single cycle cross-sectional study of associations with body size and ovulatory characteristics
Disclosure: A.V. Baaske: None. S. Shirin: None. C. Bos: None. D. Kalidasan: None. J.C. Prior: None.
Background
Tanner Breast Stage 3 (TB3, at menarche) and Tanner 5 (TB5, once ovulatory cycles established), despite being similar with an “upstanding” nipple, are different. Evidence suggests that steady and high ovulatory-level progesterone exposure accounts for the larger areolar diameter in TB5. Progesterone levels indicate whether the menstrual cycle is ovulatory and have crucial implications for women’s reproductive, metabolic, cardiovascular, and bone health. However, few data show average areolar diameter in regularly cycling women in whom SES, body size, and reproductive variables have been documented.
Objective
As a step towards better understanding the role of areolar diameter in reflecting estradiol-progesterone balance, this study aims to document the average mean bilateral lateral areolar diameter (AD) in a cohort of regularly menstruating, premenopausal women in whom ovulation was documented in one cycle. We also aim to describe relationships between AD and demographic, anthropometric, and reproductive/ovulation variables.
From February 2020 to September 2022 (during the SARS-CoV-2 pandemic), 73 women from Metro Vancouver, British Columbia participated. Women were of median (min-max) age 30 (19-35) years, BMI 24.5 (17.1-41.4) and most identified as White (61.6%) with a median of 16 years of education. Median CL was 29 days (n=65) and QBT data showed 39.3% were normally ovulatory, 34.4% had short luteal phases and 26.2% were anovulatory. Median within-woman bilateral AD was 3.85 (2.35-8.00) cm. Left AD exceeded right (L 3.8 [2.3,8.2]; R 3.7 [ 2.4,7.8]; P=.003). Larger AD (≥3.85cm) was associated with greater body size (BMI r=.534), weight and waist circumference. However, earlier age at menarche (P=.02) was also significantly associated. No other reproductive variables (cycle length, luteal phase length, parity, ever use of CHC) were related to AD before body size adjustments.
Conclusions
This study is the first to document, and describe demographic, anthropomorphic and reproductive associations with, AD in community dwelling, regularly cycling, premenopausal women. Future steps will determine the most influential of the anthropometric variables; adjustment for these will facilitate assessments of associations with ovulation related characteristics. Presentation: Monday, July 14, 2025
breast areolar diameter ovulatory status premenopausal women, Prior JC areolar diameter progesterone menstrual cycle, Tanner breast stage ovulation progesterone exposure, quantitative basal temperature QBT ovulation analysis, areolar diameter body mass index BMI association, breast development markers ovulatory disturbances, menstrual cycle diary breast physical examination cross-sectional, bilateral areolar measurement body size reproductive variables, age at menarche areolar diameter relationship, subclinical ovulatory disturbance short luteal phase anovulation detection
DOI 10.1210/jendso/bvaf149.1891 10.1210/jendso/bvaf149.1891
Cite this article
Baaske, A. V., Shirin, S., Bos, C., Kalidasan, D., & Prior, J. C. (2025). MON-154 Breast areolar diameter in healthy menstruating women—a single cycle cross-sectional study of associations with body size and ovulatory characteristics. *Journal of the Endocrine Society*, *9*(Supplement_1). https://doi.org/10.1210/jendso/bvaf149.1891
Baaske AV, Shirin S, Bos C, Kalidasan D, Prior JC. MON-154 Breast areolar diameter in healthy menstruating women—a single cycle cross-sectional study of associations with body size and ovulatory characteristics. Journal of the Endocrine Society. 2025;9(Supplement_1). doi:10.1210/jendso/bvaf149.1891
Baaske, A. V., et al. "MON-154 Breast areolar diameter in healthy menstruating women—a single cycle cross-sectional study of associations with body size and ovulatory characteristics." *Journal of the Endocrine Society*, vol. 9, no. Supplement_1, 2025.
Wood M et al., 2025
Open Access
Journal of the Endocrine Society
Disclosure: M. Wood: None. J.C. Prior: None. S. Shirin: None. A. Goshtasebi: None. Breast tenderness and swelling are associated with premenstrual symptoms but have not been well described in healthy,...
Nelson K et al., 2025
Open Access
Journal of the Endocrine Society
Disclosure: K. Nelson: None. J. Singer: None. A. Pederson: None. D. Kalidasan: None. J. Prior: None.
Polycystic ovary syndrome (PCOS) is an endocrine-metabolic disorder that significantly decreases he...
PCOS > Treatment > Progesterone TherapyPCOS > Treatment > Antiandrogen TherapyPCOS > Quality of Life > Patient-Reported Outcomes
Shirin S et al., 2020
Open Access
Journal of the Endocrine Society
Endometrial cancer1 and oligomenorrhea2 are common risks for women living with androgenic PCOS (WLWP); cyclic progesterone therapy could prevent both. Cyclic oral micronized progesterone therapy (Cycl...
Shirin S et al., 2020
Open Access
Journal of the Endocrine Society
Women living with androgenic PCOS (WLWP) experience unpredictable oligomenorrhea1 and are at increased risk for endometrial cancer2. Oral micronized progesterone (OMP) given cyclically (14 days/cycle ...